A recent study shows that menopause may worsen Multiple Sclerosis symptoms and accelerate its progression due to a decline in ...
Scientists say IRX4204 given to mice with evident symptoms showed potential "as a remyelinating and neurorestorative ...
Developed under an exclusive worldwide licence agreement with UCB, PTD802 is designed to counteract the effects of ...
News Medical on MSN2d
Pheno Therapeutics granted clinical trial authorization for lead multiple sclerosis therapeutic candidate PTD802Pheno Therapeutics Limited., a biotechnology company focused on the discovery and development of small molecule therapeutics ...
News Medical on MSN2d
Pheno Therapeutics receives clinical trial authorization for novel multiple sclerosis therapeuticPheno Therapeutics Limited., a biotechnology company focused on the discovery and development of small molecule therapeutics for the treatment of neurological diseases, announced today it has received ...
OCS-05 was well tolerated and improved vision and eye health in a Phase 2 trial in 33 people with optic neuritis due to MS or ...
Pheno Therapeutics Limited has received clinical trial authorisation (CTA) from the UK’s MHRA for its lead candidate, PTD802.
A grant from the Rosenau Family Research Foundation will examine how an enzyme deficiency in the brain leads to this fatal ...
A UB researcher working on Krabbe disease has been awarded a grant from the Rosenau Family Research Foundation to investigate ...
Oculis Holding’s OCS-05 phase 2 ACUITY trial in acute optic neuritis meets primary safety endpoint and key secondary efficacy endpoints: Zug, Switzerland Tuesday, January 7, 202 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback